These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 26697571

  • 1. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
    Bodini G, Giannini EG, Furnari M, Marabotto E, Baldissarro I, Del Nero L, Assandri L, Moscatelli A, Savarino V, Savarino E.
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G, Giannini EG, Savarino V, Del Nero L, Pellegatta G, De Maria C, Baldissarro I, Savarino E.
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [Abstract] [Full Text] [Related]

  • 3. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
    Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, Guz-Mark A, Rinawi F, Cohen S, Topf-Olivestone C, Shaoul R, Yerushalmi B, Shamir R.
    Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
    [Abstract] [Full Text] [Related]

  • 4. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML, Karim S, Helms ETJ, Keating PE, Hock B, Stamp LK, Schultz M.
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques.
    Bodini G, Demarzo MG, Djahandideh A, Ziola S, Risso P, Bertani L, Baldissarro I, Testa T, Marchi S, Savarino E, Giannini EG.
    Eur J Gastroenterol Hepatol; 2022 Apr 01; 34(4):382-388. PubMed ID: 34334710
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
    Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A.
    J Gastroenterol; 2014 Jan 01; 49(1):100-9. PubMed ID: 23575576
    [Abstract] [Full Text] [Related]

  • 8. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.
    Gastroenterology; 2015 Jun 01; 148(7):1320-9.e3. PubMed ID: 25724455
    [Abstract] [Full Text] [Related]

  • 9. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
    Zittan E, Kabakchiev B, Milgrom R, Nguyen GC, Croitoru K, Steinhart AH, Silverberg MS.
    J Crohns Colitis; 2016 May 01; 10(5):510-5. PubMed ID: 26783345
    [Abstract] [Full Text] [Related]

  • 10. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
    Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, Ferrante M.
    Aliment Pharmacol Ther; 2018 Oct 01; 48(7):731-739. PubMed ID: 30109889
    [Abstract] [Full Text] [Related]

  • 11. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Bond A, Asher R, Jackson R, Sager K, Martin K, Kneebone A, Philips S, Taylor W, Subramanian S.
    Eur J Gastroenterol Hepatol; 2016 Mar 01; 28(3):271-6. PubMed ID: 26657455
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, Mouzas I, Koutroubakis IE.
    Eur J Gastroenterol Hepatol; 2019 Feb 01; 31(2):187-191. PubMed ID: 30543573
    [Abstract] [Full Text] [Related]

  • 14. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
    Vande Casteele N, Baert F, Bian S, Dreesen E, Compernolle G, Van Assche G, Ferrante M, Vermeire S, Gils A.
    J Crohns Colitis; 2019 Sep 27; 13(10):1248-1256. PubMed ID: 30820530
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group.
    Aliment Pharmacol Ther; 2017 Nov 27; 46(9):873-882. PubMed ID: 28884856
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab.
    Bodini G, Savarino V, Peyrin-Biroulet L, de Cassan C, Dulbecco P, Baldissarro I, Fazio V, Giambruno E, Savarino E.
    Dig Liver Dis; 2014 Nov 27; 46(11):1043-6. PubMed ID: 25169962
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.